The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Knee osteoarthritis (OA) is a chronic, painful disease associated with considerable morbidity, costs and disability. It is estimated that over a third of people aged over 60 have radiographic knee OA2 and over 50% of these with knee OA will go on to have a total knee replacement in their lifetime. At present there are no licensed treatments that alter disease progress and management is primarily concerned with symptom control to retain or improve joint function, although a trial of strontium ranelate showed promising results.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 60
Healthy Volunteers: f
View:

• Primary osteoarthritis Patients recruited were between 30 to 60 years of age.

• X-ray confirmed Kellgren-Lawrence grade II or III severity primary tibiofemoral OA according to the American College of Rheumatology criteria.

Locations
Other Locations
Egypt
Mostafa Bahaa
RECRUITING
Damietta
Contact Information
Primary
Mostafa Bahaa
mbahaa@horus.edu.eg
+201025538337
Time Frame
Start Date: 2024-01-30
Estimated Completion Date: 2027-09-20
Participants
Target number of participants: 70
Treatments
Active_comparator: control group
35 patients will receive celecoxib 200 mg capsule plus placebo tablets
Active_comparator: Comparative group
35 patients will receive celecoxib 200 mg capsule plus 1000 mg metformin daily
Sponsors
Leads: Mostafa Bahaa

This content was sourced from clinicaltrials.gov